Socioeconomic status, including education and income level, appears to be tied to prostate-specific antigen test results and prostate cancer treatment and survival, but the exact nature of these associations is not yet clear.
Although cytogenetic abnormalities that arise during the course of CML are prevalent in later stages of the disease and are associated with a poorer prognosis, as many as 10% to 12% of patients exhibit ACAs at diagnosis.
Targeting tumor and extracellular LPA could help deny tumors their inflammatory habitat and improve the efficacy of radiotherapy, chemotherapy, and possibly immunotherapies.
It is not always clear whether patients who discontinue anti-PD-1 and -CTLA-4 therapy should re-initiate treatment after adverse events are resolved.
The results of this study support previous findings that psychological distress is associated with an increased risk of mortality among patients with lung cancer.
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- The Challenges of Immunotherapy Re-challenge in Metastatic Melanoma
- FDA Approves Fulvestrant/Abemaciclib Combination for Breast Cancer
- Beta-blockers May Prevent Stress-induced Lung Cancer Treatment Resistance
- NSCLC: Tissue, Rather Than Liquid, Biopsy Recommended for Identifying Resistance Mechanisms
- Can Targeting Inflammatory Microenvironments Improve Cancer Therapy Effectiveness?
- FDA Expands Sunitinib Indication To Include Adjuvant Therapy for Renal Cell Carcinoma
- Ultrasonography May Detect Thyroid Cancer Growth Arrest, Negating Need for Treatment
- Does Education Level Predict PSA Screening and Prostate Cancer Survival?
- Unrelated HSCT, UCBT May Yield Similar Survival Outcomes in Acute Leukemia
- Minimal Residual Disease and Patient Genotype May Inform Relapse Risk Algorithms in ALL